Welcome to our dedicated page for Rapt Therapeutics SEC filings (Ticker: RAPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RAPT Therapeutics, Inc. filings document the regulatory record of a clinical-stage immunology biopharmaceutical company and its transition from a Nasdaq-listed issuer to a wholly owned subsidiary of GlaxoSmithKline LLC. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentation materials, material agreements, capital-structure matters, and shareholder-related transaction disclosures.
Later filings include a Form 25 for removal of RAPT common stock from Nasdaq listing and registration, and a Form 15 covering termination of registration or suspension of reporting duties for its common stock. These documents record the completed merger, the surviving-company structure, the delisting process, and Exchange Act reporting-status changes.
OrbiMed Advisors LLC filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 0 shares of RAPT Therapeutics, Inc. common stock. The filing lists the class as Common Stock, par value $0.0001 per share (CUSIP 75382E109) and states 0.0% ownership. The filing notes that investment and voting power are exercised through a management committee of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership. The filing is signed by Carl L. Gordon on 05/15/2026.
RAPT Therapeutics, Inc. Schedule 13G/A (Amendment No. 2) was filed by RTW Investments, LP and Roderick Wong, M.D., reporting ownership information for the company's Common Stock, CUSIP 75382E208. The filing states the Reporting Persons each hold 0.0% of the class as of 03/31/2026 and list no voting or dispositive power.
The statement is a joint filing by RTW Investments (a Delaware limited partnership) and Dr. Wong as Managing Partner; signatures are dated 05/15/2026. The filing incorporates a Joint Filing Agreement by reference.
RAPT Therapeutics director Lori Lyons-Williams reported the cash-out of equity awards tied to the company’s acquisition by GSK. On March 3, 2026, multiple director stock options and 4,956 common shares were disposed of pursuant to a tender offer and merger at $58.00 per share, with RSUs and options cancelled and converted into cash under the Merger Agreement.
RAPT Therapeutics director Mary Ann Gray reported dispositions of stock options and shares tied to the company’s acquisition by a GlaxoSmithKline affiliate. On March 3, 2026, a GlaxoSmithKline LLC subsidiary completed a tender offer and merger, acquiring all RAPT common stock for $58.00 per share in cash.
Under the merger agreement, all outstanding restricted stock units were cancelled and converted into the right to receive cash based on the $58.00 offer price. Director stock options were accelerated and, if in the money, converted into cash based on the spread to the offer price; options with exercise prices above $58.00 were cancelled for no consideration. Gray also disposed of 4,956 common shares pursuant to the tender offer.
RAPT Therapeutics director Michael F. Giordano reported the disposition of equity awards and shares in connection with the company’s acquisition by GlaxoSmithKline. The filing shows multiple Director Stock Options and 4,956 shares of common stock disposed on March 3, 2026, including a disposition pursuant to a tender offer.
Under a Merger Agreement dated January 19, 2026, a GSK subsidiary completed a tender offer to acquire all outstanding RAPT shares for $58.00 per share in cash, followed by a merger that made RAPT an indirect wholly owned subsidiary. At the merger’s effective time, all outstanding RSUs were cancelled and converted into cash based on the Offer Price, and stock options were accelerated; in-the-money options were cashed out using the Offer Price while out-of-the-money options were cancelled without consideration.
RAPT Therapeutics director Ashley L. Dombkowski reported disposing of equity awards in connection with the company’s acquisition by a GlaxoSmithKline affiliate. On March 3, 2026, 25,000 director stock options and 4,956 shares of common stock were surrendered to the issuer or purchaser as part of the closing.
Under a previously signed Merger Agreement, a GlaxoSmithKline subsidiary completed a tender offer to acquire all RAPT common shares for $58.00 per share in cash, then merged with RAPT, which became an indirect wholly owned subsidiary. At the merger’s effective time, all outstanding RSUs and eligible stock options were cancelled and converted into the right to receive cash based on the $58.00 offer price.
RAPT Therapeutics’ chief financial officer, Rodney KB Young, reported the cash-out of equity awards tied to the company’s acquisition by GlaxoSmithKline. The filing shows dispositions of several employee stock options back to the issuer and the tender of 3,304 common shares.
Under a merger agreement with GlaxoSmithKline LLC and its affiliates, all RAPT common shares were acquired for $58.00 per share in cash. Stock options with exercise prices below this offer price were accelerated, then cancelled in exchange for cash equal to their in-the-money value.
Certain unvested options granted after March 1, 2025 were instead converted into cash-based awards of the GSK parent. These converted awards retain the original vesting conditions but pay out 50% at closing and 50% nine months later, with full acceleration if the holder is involuntarily terminated within that nine-month period.
RAPT Therapeutics chief scientific officer Dirk G. Brockstedt reported dispositions of common stock and employee stock options tied to the company’s acquisition by a GlaxoSmithKline subsidiary. All transactions occurred on March 3, 2026, when Redrose Acquisition Co. merged with RAPT.
Under a January 19, 2026 Merger Agreement, a tender offer acquired all RAPT common shares at $58.00 per share in cash. At the merger’s effective time, each share of common stock held by the reporting person was exchanged for the cash offer price. All outstanding stock options became fully vested immediately before closing.
In-the-money options were cancelled and converted into a right to receive cash equal to the number of option shares multiplied by the excess of the $58.00 offer price over the applicable exercise price, while out-of-the-money options were cancelled for no consideration. Certain unvested options granted after March 1, 2025 were instead converted into cash-based awards of GlaxoSmithKline LLC, preserving prior vesting terms.
Wong Brian Russell reported disposition transactions in this Form 4 filing.
RAPT Therapeutics President and CEO Brian Russell Wong reported multiple equity disposals tied to the company’s sale to GlaxoSmithKline. On March 3, 2026, his common shares were tendered for $58.00 per share in cash under a completed tender offer and merger.
Employee stock options were adjusted for a prior 1-for-8 reverse stock split and, at the merger’s effective time, became fully vested. Options with exercise prices below $58.00 were cancelled and converted into rights to receive cash based on the spread between the offer price and each option’s exercise price.
Certain unvested options granted after March 1, 2025 were instead converted into cash-based awards of the acquirer, with payments scheduled 50% at closing and 50% nine months later, subject to continued service and accelerated payout upon qualifying involuntary termination.